Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis

Journal of Neuroinflammation

Volumn 9, Issue , 2012, Pages

  Romme Christensen, Jeppe ^a   Börnsen, Lars ^a   Hesse, Dan ^a   Krakauer, Martin ^a   Sørensen, Per S ^a   Søndergaard, Helle B ^a   Sellebjerg, Finn ^a  

^a International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

Author keywords

Blood; Cerebrospinal fluid cells; Cytokines; Immunology; Real time PCR; Relapsing remitting multiple sclerosis

Indexed keywords

CD14 ANTIGEN; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 12P35; INTERLEUKIN 15; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 27; INTERLEUKIN 7; LYMPHOTOXIN; LYMPHOTOXIN BETA;

ADULT; ARTICLE; B LYMPHOCYTE; CD19 GENE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IFNG GENE; IL GENE; IL10 GENE; IL12A GENE; IL15 GENE; IL1B GENE; IL23 GENE; IL27 GENE; IL7 GENE; IMMUNOPATHOGENESIS; LTA GENE; LTB GENE; LYMPHOCYTE SUBPOPULATION; MALE; MONOCYTE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NEUROLOGIC DISEASE; NON INFLAMMATORY NEUROLOGICAL DISEASE; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; RELAPSE; REMISSION; T LYMPHOCYTE;

EID: 84866173359     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-9-215     Document Type: Article

References (45)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2008, 372:1502-1517. 10.1016/S0140-6736(08)61620-7, 18970977.
2. Cepok S, Jacobsen M, Schock S, Omer B, Jaekel S, Boddeker I, Oertel WH, Sommer N, Hemmer B. Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis. Brain 2001, 124:2169-2176. 10.1093/brain/124.11.2169, 11673319.
3. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW, . AFFIRM Investigators A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354:899-910. 10.1056/NEJMoa044397, 16510744, AFFIRM Investigators.
4. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH, . HERMES Trial Group B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008, 358:676-688. 10.1056/NEJMoa0706383, 18272891, HERMES Trial Group.
5. Khademi M, Bornsen L, Rafatnia F, Andersson M, Brundin L, Piehl F, Sellebjerg F, Olsson T. The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers. Eur J Neurol 2009, 16:528-536. 10.1111/j.1468-1331.2009.02532.x, 19220425.
6. del Pilar Martin M, Cravens PD, Winger R, Frohman EM, Racke MK, Eagar TN, Zamvil SS, Weber MS, Hemmer B, Karandikar NJ, Kleinschmidt-DeMasters BK, Stüve O. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol 2008, 65:1596-1603. 10.1001/archneur.65.12.noc80051, 18852339.
7. Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons JA. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 2006, 180:63-70. 10.1016/j.jneuroim.2006.06.029, 1769354, 16904756.
8. Kebir H, Ifergan I, Alvarez JI, Bernard M, Poirier J, Arbour N, Duquette P, Prat A. Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Ann Neurol 2009, 66:390-402. 10.1002/ana.21748, 19810097.
9. Van-Zwam M, Huizinga R, Melief MJ, Wierenga-Wolf AF, Van-Meurs M, Voerman JS, Biber KP, Boddeke HW, Hopken UE, Meisel C, Meisel A, Bechmann I, Hintzen RQ, T-Hart BA, Amor S, Laman JD, Boven LA. Brain antigens in functionally distinct antigen-presenting cell populations in cervical lymph nodes in MS and EAE. J Mol Med (Berl) 2009, 87:273-286.
10. Kivisakk P, Imitola J, Rasmussen S, Elyaman W, Zhu B, Ransohoff RM, Khoury SJ. Localizing central nervous system immune surveillance: meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis. Ann Neurol 2009, 65:457-469. 10.1002/ana.21379, 3305810, 18496841.
11. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005, 23:683-747. 10.1146/annurev.immunol.23.021704.115707, 15771584.
12. Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987, 1:893-895.
13. Krakowski M, Owens T. Interferon-gamma confers resistance to experimental allergic encephalomyelitis. Eur J Immunol 1996, 26:1641-1646. 10.1002/eji.1830260735, 8766573.
14. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 2003, 100:9440-9445. 10.1073/pnas.1530509100, 170937, 12883005.
15. Krakauer M, Sorensen P, Khademi M, Olsson T, Sellebjerg F. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression. Mult Scler 2008, 14:622-630. 10.1177/1352458507087136, 18424480.
16. Brentano F, Ospelt C, Stanczyk J, Gay RE, Gay S, Kyburz D. Abundant expression of the interleukin (IL)23 subunit p19, but low levels of bioactive IL23 in the rheumatoid synovium: differential expression and Toll-like receptor-(TLR) dependent regulation of the IL23 subunits, p19 and p40, in rheumatoid arthritis. Ann Rheum Dis 2009, 68:143-150.
17. Yeo L, Toellner KM, Salmon M, Filer A, Buckley CD, Raza K, Scheel-Toellner D. Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis. Ann Rheum Dis 2011, 70:2022-2028. 10.1136/ard.2011.153312, 3184241, 21742639.
18. Salmaggi A, Sandberg-Wollheim M. Monocyte phenotype in blood and cerebrospinal fluid: compartment-specific pattern is unrelated to neurological disease. J Neurol Sci 1993, 120:201-207. 10.1016/0022-510X(93)90274-3, 8138810.
19. Ifergan I, Kebir H, Bernard M, Wosik K, Dodelet-Devillers A, Cayrol R, Arbour N, Prat A. The blood-brain barrier induces differentiation of migrating monocytes into Th17-polarizing dendritic cells. Brain 2008, 131:785-799. 10.1093/brain/awm295, 18156156.
20. Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995, 37:424-435. 10.1002/ana.410370404, 7536402.
21. Hesse D, Krakauer M, Lund H, Sondergaard HB, Limborg SJ, Sorensen PS, Sellebjerg F. Disease protection and interleukin-10 induction by endogenous interferon-beta in multiple sclerosis?. Eur J Neurol 2011, 18:266-272. 10.1111/j.1468-1331.2010.03116.x, 20561040.
22. Cucci A, Barbero P, Clerico M, Ferrero B, Versino E, Contessa G, Demercanti S, Viglietta E, Di Liberto A, Vai AG, Durelli L. Pro-inflammatory cytokine and chemokine mRNA blood level in multiple sclerosis is related to treatment response and interferon-beta dose. J Neuroimmunol 2010, 226:150-157. 10.1016/j.jneuroim.2010.05.038, 20573405.
23. Calabresi PA, Tranquill LR, McFarland HF, Cowan EP. Cytokine gene expression in cells derived from CSF of multiple sclerosis patients. J Neuroimmunol 1998, 89:198-205. 10.1016/S0165-5728(98)00139-8, 9726843.
24. Hulshof S, Montagne L, De Groot CJ, Van Der Valk P. Cellular localization and expression patterns of interleukin-10, interleukin-4, and their receptors in multiple sclerosis lesions. Glia 2002, 38:24-35. 10.1002/glia.10050, 11921201.
25. Navikas V, Link J, Palasik W, Soderstrom M, Fredrikson S, Olsson T, Link H. Increased mRNA expression of IL-10 in mononuclear cells in multiple sclerosis and optic neuritis. Scand J Immunol 1995, 41:171-178. 10.1111/j.1365-3083.1995.tb03550.x, 7532318.
26. Ozenci V, Kouwenhoven M, Huang YM, Kivisakk P, Link H. Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-alpha)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-beta) treatment. Clin Exp Immunol 2000, 120:147-153. 10.1046/j.1365-2249.2000.01175.x, 1905623, 10759776.
27. Ozenci V, Kouwenhoven M, Huang YM, Xiao B, Kivisakk P, Fredrikson S, Link H. Multiple sclerosis: levels of interleukin-10-secreting blood mononuclear cells are low in untreated patients but augmented during interferon-beta-1b treatment. Scand J Immunol 1999, 49:554-561. 10.1046/j.1365-3083.1999.00546.x, 10320650.
28. Carrieri PB, Provitera V, De Rosa T, Tartaglia G, Gorga F, Perrella O. Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis: a correlation with clinical activity. Immunopharmacol Immunotoxicol 1998, 20:373-382. 10.3109/08923979809034820, 9736442.
29. Khademi M, Illes Z, Gielen AW, Marta M, Takazawa N, Baecher-Allan C, Brundin L, Hannerz J, Martin C, Harris RA, Hafler DA, Kuchroo VK, Olsson T, Piehl F, Wallström E. T Cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis. J Immunol 2004, 172:7169-7176.
30. Iacobaeus E, Amoudruz P, Strom M, Khademi M, Brundin L, Hillert J, Kockum I, Malmström V, Olsson T, Tham E, Piehl F. The expression of VEGF-A is down regulated in peripheral blood mononuclear cells of patients with secondary progressive multiple sclerosis. PLoS One 2011, 6:e19138. 10.1371/journal.pone.0019138, 3089609, 21573104.
31. Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z, Freeman C, Hunt SE, Edkins S, Gray E, Booth DR, Potter SC, Goris A, Band G, Oturai AB, Strange A, Saarela J, Bellenguez C, Fontaine B, Gillman M, Hemmer B, Gwilliam R, Zipp F, Jayakumar A, Martin R, Leslie S, Hawkins S, Giannoulatou E, , et al. International Multiple Sclerosis Genetics Consortium Wellcome Trust Case Control Consortium 2 Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476:214-219. 10.1038/nature10251, 3182531, 21833088, International Multiple Sclerosis Genetics Consortium Wellcome Trust Case Control Consortium 2.
32. Kremlev SG, Gaurnier-Hausser AL, Del Valle L, Perez-Liz G, Dimitrov S, Tuszynski G. Angiocidin promotes pro-inflammatory cytokine production and antigen presentation in multiple sclerosis. J Neuroimmunol 2008, 194:132-142. 10.1016/j.jneuroim.2007.11.003, 18207252.
33. Baranzini SE, Elfstrom C, Chang SY, Butunoi C, Murray R, Higuchi R, Oksenberg JR. Transcriptional analysis of multiple sclerosis brain lesions reveals a complex pattern of cytokine expression. J Immunol 2000, 165:6576-6582.
34. Lundmark F, Duvefelt K, Iacobaeus E, Kockum I, Wallstrom E, Khademi M, Oturai A, Ryder LP, Saarela J, Harbo HF, Celius EG, Salter H, Olsson T, Hillert J. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet 2007, 39:1108-1113. 10.1038/ng2106, 17660816.
35. Kivisakk P, Matusevicius D, He B, Soderstrom M, Fredrikson S, Link H. IL-15 mRNA expression is up-regulated in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis (MS). Clin Exp Immunol 1998, 111:193-197. 10.1046/j.1365-2249.1998.00478.x, 1904841, 9472681.
36. Lee LF, Axtell R, Tu GH, Logronio K, Dilley J, Yu J, Rickert M, Han B, Evering W, Walker MG, Shi J, de Jong BA, Killestein J, Polman CH, Steinman L, Lin JC. IL-7 promotes T(H)1 development and serum IL-7 predicts clinical response to interferon-beta in multiple sclerosis. Sci Transl Med 2011, 3:93ra68. 10.1126/scitranslmed.3002400, 21795588.
37. Vaknin-Dembinsky A, Brass SD, Gandhi R, Weiner HL. Membrane bound IL-15 is increased on CD14 monocytes in early stages of MS. J Neuroimmunol 2008, 195:135-139. 10.1016/j.jneuroim.2008.01.016, 2747383, 18378324.
38. Gomez-Nicola D, Spagnolo A, Guaza C, Nieto-Sampedro M. Aggravated experimental autoimmune encephalomyelitis in IL-15 knockout mice. Exp Neurol 2010, 222:235-242. 10.1016/j.expneurol.2009.12.034, 20070942.
39. Selmaj K, Raine CS, Cannella B, Brosnan CF. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 1991, 87:949-954. 10.1172/JCI115102, 329886, 1999503.
40. Matusevicius D, Navikas V, Soderstrom M, Xiao BG, Haglund M, Fredrikson S, Link H. Multiple sclerosis: the proinflammatory cytokines lymphotoxin-alpha and tumour necrosis factor-alpha are upregulated in cerebrospinal fluid mononuclear cells. J Neuroimmunol 1996, 66:115-123. 10.1016/0165-5728(96)00032-X, 8964905.
41. Buckle GJ, Hollsberg P, Hafler DA. Activated CD8+ T cells in secondary progressive MS secrete lymphotoxin. Neurology 2003, 60:702-705. 10.1212/01.WNL.0000048204.89346.30, 12601116.
42. Aloisi F, Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 2006, 6:205-217. 10.1038/nri1786, 16498451.
43. Bar-Or A, Fawaz L, Fan B, Darlington PJ, Rieger A, Ghorayeb C, Calabresi PA, Waubant E, Hauser SL, Zhang J, Smith CH. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?. Ann Neurol 2010, 67:452-461. 10.1002/ana.21939, 20437580.
44. Sellebjerg F, Jensen J, Ryder LP. Costimulatory CD80 (B7-1) and CD86 (B7-2) on cerebrospinal fluid cells in multiple sclerosis. J Neuroimmunol 1998, 84:179-187. 10.1016/S0165-5728(97)00261-0, 9628461.
45. Sellebjerg F, Jensen J, Jensen CV, Wiik A. Expansion of CD5 - B cells in multiple sclerosis correlates with CD80 (B7-1) expression. Scand J Immunol 2002, 56:101-107. 10.1046/j.1365-3083.2002.01108.x, 12100477.